Patient Blood Management Market

Executive Summary

Patient Blood Management Market was valued at US $13.08 billion in 2021 and is projected to grow at 8.34% CAGR over the forecast period to reach US $21.14 billion by 2027. Patient Blood Management Market represented US $1.94 billion opportunity over 2019-2021 and estimated to create US $8.07 billion opportunity in 2027 over 2021.

Patient Blood Management from Consainsights analyses the Patient Blood Management Market in the Life Sciences industry over the forecast period to 2027.

Patient Blood Management research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Patient Blood Management segmentation includes Product, Component, End User, Region and Geography.

Based on the Product, the Patient Blood Management analysis covers Instruments, Accessories, Reagents and Kits, Software.

In Product segment, Instruments segment has highest cagr growth of 7.38%.

Based on the Component, the Patient Blood Management analysis covers Whole Blood & Red Blood Cells, Plasma.

In Component segment, Whole Blood & Red Blood Cells segment has highest cagr growth of 7.38%.

Based on the End User, the Patient Blood Management analysis covers Blood Banks, Hospitals, Diagnostic Clinics and & Pathology Labs.

In End User segment, Blood Banks segment has highest cagr growth of 7.38%.

Based on the Region, the Patient Blood Management analysis covers North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

In Region segment, North America segment has highest cagr growth of 7.38%.

Based on the region, the Patient Blood Management analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Haemonetics Corporation, Fresenius Se & Co. KGaA, Terumo Corporation, Immucor, Inc., B. Braun Melsungen AG, Macopharma, Biomérieux SA, Asahi Kasei Medical Co. Ltd. (A Subsidiary of Asahi Kasei Corporation), Kaneka Corporation, Bio-Rad Laboratories, Inc., Abbott Laboratories, Grifols, S.A., F. Hoffmann-La Roche LTD., Livanova PLC, Danaher Corporation, Other Companies and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product

Introduction

In 2021, Instruments segment has the highest revenue of US $6.66 billion and is expected to grow at CAGR of 7.38% by 2027 Instruments segment has highest cagr growth of 7.38%.

Instruments

Instruments segment was valued at US $5.68 billion in 2019 and is projected to grow at 7.38% CAGR over the forecast period to reach US $10.77 billion by 2027. Instruments segment represented US $0.99 billion opportunity over 2019-2021 and estimated to create US $4.11 billion opportunity in 2027 over 2021.

Accessories

Accessories segment was valued at US $2.87 billion in 2019 and is projected to grow at 7.38% CAGR over the forecast period to reach US $5.44 billion by 2027. Accessories segment represented US $0.50 billion opportunity over 2019-2021 and estimated to create US $2.08 billion opportunity in 2027 over 2021.

Reagents and Kits

Reagents and Kits segment was valued at US $1.29 billion in 2019 and is projected to grow at 7.38% CAGR over the forecast period to reach US $2.46 billion by 2027. Reagents and Kits segment represented US $0.22 billion opportunity over 2019-2021 and estimated to create US $0.94 billion opportunity in 2027 over 2021.

Software

Software segment was valued at US $1.30 billion in 2019 and is projected to grow at 7.38% CAGR over the forecast period to reach US $2.47 billion by 2027. Software segment represented US $0.23 billion opportunity over 2019-2021 and estimated to create US $0.94 billion opportunity in 2027 over 2021.

Component

Introduction

In 2021, Plasma segment has the highest revenue of US $8.17 billion and is expected to grow at CAGR of 7.38% by 2027 Whole Blood & Red Blood Cells segment has highest cagr growth of 7.38%.

Whole Blood & Red Blood Cells

Whole Blood & Red Blood Cells segment was valued at US $4.18 billion in 2019 and is projected to grow at 7.38% CAGR over the forecast period to reach US $7.93 billion by 2027. Whole Blood & Red Blood Cells segment represented US $0.73 billion opportunity over 2019-2021 and estimated to create US $3.02 billion opportunity in 2027 over 2021.

Plasma

Plasma segment was valued at US $6.96 billion in 2019 and is projected to grow at 7.38% CAGR over the forecast period to reach US $13.21 billion by 2027. Plasma segment represented US $1.21 billion opportunity over 2019-2021 and estimated to create US $5.04 billion opportunity in 2027 over 2021.

End User

Introduction

In 2021, Blood Banks segment has the highest revenue of US $5.42 billion and is expected to grow at CAGR of 7.38% by 2027 Blood Banks segment has highest cagr growth of 7.38%.

Blood Banks

Blood Banks segment was valued at US $4.62 billion in 2019 and is projected to grow at 7.38% CAGR over the forecast period to reach US $8.76 billion by 2027. Blood Banks segment represented US $0.80 billion opportunity over 2019-2021 and estimated to create US $3.34 billion opportunity in 2027 over 2021.

Hospitals

Hospitals segment was valued at US $3.80 billion in 2019 and is projected to grow at 7.38% CAGR over the forecast period to reach US $7.21 billion by 2027. Hospitals segment represented US $0.66 billion opportunity over 2019-2021 and estimated to create US $2.75 billion opportunity in 2027 over 2021.

Diagnostic Clinics and & Pathology Labs

Diagnostic Clinics and & Pathology Labs segment was valued at US $2.72 billion in 2019 and is projected to grow at 7.38% CAGR over the forecast period to reach US $5.17 billion by 2027. Diagnostic Clinics and & Pathology Labs segment represented US $0.47 billion opportunity over 2019-2021 and estimated to create US $1.97 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, North America segment has the highest revenue of US $5.28 billion and is expected to grow at CAGR of 7.38% by 2027 North America segment has highest cagr growth of 7.38%.

North America

North America segment was valued at US $4.50 billion in 2019 and is projected to grow at 7.38% CAGR over the forecast period to reach US $8.54 billion by 2027. North America segment represented US $0.78 billion opportunity over 2019-2021 and estimated to create US $3.26 billion opportunity in 2027 over 2021.

Europe

Europe segment was valued at US $2.77 billion in 2019 and is projected to grow at 7.38% CAGR over the forecast period to reach US $5.25 billion by 2027. Europe segment represented US $0.48 billion opportunity over 2019-2021 and estimated to create US $2.00 billion opportunity in 2027 over 2021.

Asia Pacific

Asia Pacific segment was valued at US $1.52 billion in 2019 and is projected to grow at 7.38% CAGR over the forecast period to reach US $2.88 billion by 2027. Asia Pacific segment represented US $0.26 billion opportunity over 2019-2021 and estimated to create US $1.10 billion opportunity in 2027 over 2021.

Latin America

Latin America segment was valued at US $1.45 billion in 2019 and is projected to grow at 7.38% CAGR over the forecast period to reach US $2.75 billion by 2027. Latin America segment represented US $0.25 billion opportunity over 2019-2021 and estimated to create US $1.05 billion opportunity in 2027 over 2021.

Middle East & Africa

Middle East & Africa segment was valued at US $0.90 billion in 2019 and is projected to grow at 7.38% CAGR over the forecast period to reach US $1.71 billion by 2027. Middle East & Africa segment represented US $0.16 billion opportunity over 2019-2021 and estimated to create US $0.65 billion opportunity in 2027 over 2021.